CpG
Oligodeoxynucleotide Market, by Source (Natural Source and Chemical
Synthesis), by End User (Research Institutes, Hospitals, Contract Research
Organizations, Pharmaceutical Companies, and Others), and by Geography (North
America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Size,
Share, Outlook, and Opportunity Analysis, 2018 – 2026
CpG oligodeoxynucleotide (CpG
ODN) is a synthetic oligodeoxynucleotide, which contains unmethylated CpG
motifs derived from bacterial DNA with immunostimulatory activities. CpG ODN is
a short single-stranded synthetic DNA molecule, which contains one of each of
cytosine triphosphate deoxynucleotide and guanine triphosphate deoxynucleotide
that makes up the C component in the molecule.
The CpG motifs are considered
pathogen-associated molecular patterns (PAMPs), as they are present in microbial
genomes in abundance, but are rarely present in vertebrate genomes. These CpG
PAMPs are recognized by the pattern recognition receptor (PRR) toll-like
receptor 9 (TLR9), which is constitutively expressed only in B cells and
plasmacytoid dendritic cells (pDCs) in humans and other higher primates. CpG
ODNs show great potential for attachment in prophylactic vaccines designed to
prevent infection. Various research companies are targeting synthetic CpG ODN
due to the type I pro-inflammatory response it produces and its successful use
as vaccine adjuvants.
* The sample copy includes: Report Summary, Table of
Contents, Segmentation, Competitive Landscape, Report Structure, Methodology.
Request a sample copy
of this report: https://www.coherentmarketinsights.com/insight/request-sample/2367
CpG Oligodeoxynucleotide Market –
Dynamics
Increasing demand for vaccination
across the globe is expected to contribute to significant growth of the CpG
oligodeoxynucleotide market over the forecast period. For instance, according
to the UNICEF-Vaccination & Immunization Statistics, in 2017, around 123
million children got immunized with lifesaving vaccines across the world.
Moreover, according to the Centers for Disease Control and Prevention (CDC), at
least 3,153,876,236 doses of vaccines were distributed in the U.S. from 2006 to
2016.
Rising prevalence of new chronic
diseases and the demand for reducing the occurrence of childhood diseases such
as polio and others are expected to propel growth of the CpG oligodeoxynucleotide
market. According to the Centers for Disease Control and Prevention (CDC),
around 25.3 per 100,000 children die at the age of 1-4 years due to congenital
malformations, deformations, and chromosomal abnormalities, and others.
CpG Oligodeoxynucleotide Market –
Regional Insights
On the basis of geography, the
global CpG oligodeoxynucleotide market is segmented into North America, Europe,
Latin America, Asia Pacific, Middle East, and Africa. North America held
dominant position in the global CpG oligodeoxynucleotide market in 2017. This
is owing to high mortality due to various diseases such as pneumonia,
diphtheria, pertussis, and others is expected to propel growth of the market in
this region. For instance, according to the Centers for Disease Control &
Prevention (CDC), in 2016, around 48,632 children died from pneumonia, which
was around 15.1 per 100,000 population in the U.S.
Browse Research
Report: https://www.coherentmarketinsights.com/ongoing-insight/cpg-oligodeoxynucleotide-market-2367
Moreover, Asia pacific is
expected to witness significant growth in the CpG oligodeoxynucleotide market,
owing to rising focus on R&D along with mass manufacturing of cheap and
affordable vaccines in the region. For instance, according to the International
Vaccine Institute (IVI), India became the new hub for vaccine research with
over 60% of the world’s vaccines manufactured in India in 2016.
CpG Oligodeoxynucleotide Market –
Competitive Landscape
Major players operating in the
global CpG oligodeoxynucleotide market include Novus Biologicals, InvivoGen,
Merck KGaA, Hycult Biotech, Miltenyi Biotec, Sapphire Bioscience, Biomol GmbH,
and Cosmobio. Key players are focused on adopting market strategies such as
mergers and acquisitions, and new product development, in order to retain
dominant position in the market. For instance, in July 2014, Techne Corporation
acquired Novus Biologicals, a Colorado-based supplier of outsourced and
in-house developed antibodies for life science research, for around US$ 60 million
in cash.
Buy-Now this research
report: https://www.coherentmarketinsights.com/insight/buy-now/2367
About
Coherent Market Insights:
Coherent
Market Insights is a prominent market research and consulting firm offering
action-ready syndicated research reports, custom market analysis, consulting
services, and competitive analysis through various recommendations related to
emerging market trends, technologies, and potential absolute dollar opportunity.
Contact
Us:
mailto:sales@coherentmarketinsights.com
U.S.
Office:
Name: Mr. Shah
Coherent
Market Insights 1001 4th Ave,
# 3200
Seattle, WA 98154, U.S.
US : +1-206-701-6702
UK : +44-020-8133-4027
JAPAN
: +050-5539-1737
No comments:
Post a Comment